EP2505189 - Stabilizing alkylglycoside compositions and method thereof [Right-click to bookmark this link] | Status | No opposition filed within time limit Status updated on 14.06.2019 Database last updated on 31.08.2024 | |
Former | The patent has been granted Status updated on 06.07.2018 | ||
Former | Grant of patent is intended Status updated on 14.03.2018 | ||
Former | Examination is in progress Status updated on 02.02.2018 | ||
Former | Grant of patent is intended Status updated on 01.10.2017 | ||
Former | Examination is in progress Status updated on 09.01.2017 | Most recent event Tooltip | 09.07.2021 | Lapse of the patent in a contracting state New state(s): HU | published on 11.08.2021 [2021/32] | Applicant(s) | For all designated states Aegis Therapeutics, LLC 16870 W. Bernardo Drive, Suite 390 San Diego CA 92127 / US | [2018/32] |
Former [2012/40] | For all designated states Aegis Therapeutics, LLC 16870 W. Bernardo Drive, Suite 390 San Diego CA 92127 / US | Inventor(s) | 01 /
Maggio, Edward T. 18775 Bernardo Trails Drive San Diego, California 92128 / US | [2012/40] | Representative(s) | Lee, Nicholas John, et al Kilburn & Strode LLP Lacon London 84 Theobalds Road London WC1X 8NL / GB | [2018/32] |
Former [2012/40] | Crooks, Elizabeth Caroline, et al Kilburn & Strode LLP 20 Red Lion Street London WC1R 4PJ / GB | Application number, filing date | 12165052.7 | 23.06.2006 | [2012/40] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | EP2505189 | Date: | 03.10.2012 | Language: | EN | [2012/40] | Type: | B1 Patent specification | No.: | EP2505189 | Date: | 08.08.2018 | Language: | EN | [2018/32] | Search report(s) | (Supplementary) European search report - dispatched on: | EP | 03.09.2012 | Classification | IPC: | A61K9/19, A61K47/26, A61K38/17, A61K38/28, A61K39/21, A61K38/08, A61K38/21, A61K38/27, A61K38/29, C12N7/00, A61K38/18 | [2017/37] | CPC: |
A61K47/26 (EP);
A61K38/095 (EP,US);
A61K38/1816 (EP);
A61K38/21 (EP);
A61K38/27 (EP);
A61K38/28 (EP);
A61K38/29 (EP);
A61K9/0019 (EP);
A61K9/0043 (EP);
|
Former IPC [2012/40] | A61K9/00, A61K9/19, A61K47/26, A61K38/17, A61K38/28, A61K39/21 | Designated contracting states | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR [2018/32] |
Former [2012/40] | AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR | Title | German: | Stabilisierung von Alkylglykosidzusammensetzungen und zugehöriges Verfahren | [2012/40] | English: | Stabilizing alkylglycoside compositions and method thereof | [2012/40] | French: | Stabilisation de compositions alkylglycosidiques et procédé correspondant | [2012/40] | Examination procedure | 18.01.2013 | Amendment by applicant (claims and/or description) | 18.01.2013 | Examination requested [2013/09] | 17.05.2013 | Despatch of a communication from the examining division (Time limit: M06) | 18.10.2013 | Reply to a communication from the examining division | 27.05.2015 | Despatch of a communication from the examining division (Time limit: M06) | 07.12.2015 | Reply to a communication from the examining division | 21.03.2016 | Despatch of a communication from the examining division (Time limit: M06) | 28.10.2016 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time | 06.01.2017 | Reply to a communication from the examining division | 02.10.2017 | Communication of intention to grant the patent | 01.02.2018 | Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO | 15.03.2018 | Communication of intention to grant the patent | 02.07.2018 | Fee for grant paid | 02.07.2018 | Fee for publishing/printing paid | 02.07.2018 | Receipt of the translation of the claim(s) | Parent application(s) Tooltip | EP06785482.8 / EP2076281 | EP09162179.7 / EP2158898 | Divisional application(s) | The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued (EP20060785482) is 13.04.2010 | Opposition(s) | 09.05.2019 | No opposition filed within time limit [2019/29] | Request for further processing for: | The application is deemed to be withdrawn due to failure to reply to the examination report | 06.01.2017 | Request for further processing filed | 06.01.2017 | Full payment received (date of receipt of payment) Request granted | 26.01.2017 | Decision despatched | Fees paid | Renewal fee | 25.07.2012 | Renewal fee patent year 03 | 25.07.2012 | Renewal fee patent year 04 | 25.07.2012 | Renewal fee patent year 05 | 25.07.2012 | Renewal fee patent year 06 | 25.07.2012 | Renewal fee patent year 07 | 27.06.2013 | Renewal fee patent year 08 | 30.06.2014 | Renewal fee patent year 09 | 29.06.2015 | Renewal fee patent year 10 | 27.06.2016 | Renewal fee patent year 11 | 27.06.2017 | Renewal fee patent year 12 | 27.06.2018 | Renewal fee patent year 13 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Lapses during opposition Tooltip | HU | 23.06.2006 | AT | 08.08.2018 | CY | 08.08.2018 | CZ | 08.08.2018 | DK | 08.08.2018 | EE | 08.08.2018 | ES | 08.08.2018 | FI | 08.08.2018 | IT | 08.08.2018 | LT | 08.08.2018 | LV | 08.08.2018 | MC | 08.08.2018 | NL | 08.08.2018 | PL | 08.08.2018 | RO | 08.08.2018 | SE | 08.08.2018 | SI | 08.08.2018 | SK | 08.08.2018 | TR | 08.08.2018 | BG | 08.11.2018 | GR | 09.11.2018 | IS | 08.12.2018 | PT | 08.12.2018 | [2021/32] |
Former [2021/26] | AT | 08.08.2018 | |
CY | 08.08.2018 | ||
CZ | 08.08.2018 | ||
DK | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
MC | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SI | 08.08.2018 | ||
SK | 08.08.2018 | ||
TR | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
PT | 08.12.2018 | ||
Former [2020/29] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
DK | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
MC | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SI | 08.08.2018 | ||
SK | 08.08.2018 | ||
TR | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
PT | 08.12.2018 | ||
Former [2020/16] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
DK | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
MC | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SI | 08.08.2018 | ||
SK | 08.08.2018 | ||
TR | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2020/08] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
DK | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
MC | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SI | 08.08.2018 | ||
SK | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/37] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
DK | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SI | 08.08.2018 | ||
SK | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/26] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
DK | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SK | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/23] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
EE | 08.08.2018 | ||
ES | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
SK | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/22] | AT | 08.08.2018 | |
CZ | 08.08.2018 | ||
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
RO | 08.08.2018 | ||
SE | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/21] | AT | 08.08.2018 | |
FI | 08.08.2018 | ||
IT | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
SE | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/13] | AT | 08.08.2018 | |
FI | 08.08.2018 | ||
LT | 08.08.2018 | ||
LV | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
SE | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/10] | AT | 08.08.2018 | |
FI | 08.08.2018 | ||
LT | 08.08.2018 | ||
NL | 08.08.2018 | ||
PL | 08.08.2018 | ||
SE | 08.08.2018 | ||
BG | 08.11.2018 | ||
GR | 09.11.2018 | ||
IS | 08.12.2018 | ||
Former [2019/09] | FI | 08.08.2018 | |
LT | 08.08.2018 | ||
NL | 08.08.2018 | ||
IS | 08.12.2018 | ||
Former [2019/08] | FI | 08.08.2018 | |
LT | 08.08.2018 | ||
IS | 08.12.2018 | ||
Former [2019/07] | LT | 08.08.2018 | Documents cited: | Search | [XI]WO2006025882 (UAB RESEARCH FOUNDATION [US], et al) [X] 1,2,4-9,11,13,15 * claims 1,2,8,17,47,90,94,123,131 * * paragraphs [0008] , [0016] , [0021] , [0033] , [0034] , [0037] , [0070] , [0079] , [0104] , [0072] , [0058] , [0119] * * example 1 *[I] 12,14 | Examination | - Hiroshi Tachibana ET AL, "Differentiation of Entamoeba histolytica from E. dispar facilitated by monoclonal antibodies against a 150-kDa surface antigen", Parasitol Res, doi:10.1111/j.1423-0410.2006.00879.x, (19970501), pages 435 - 439, URL: https://rd.springer.com/article/10.1007/s004360050276, (20160310), XP055257334 DOI: http://dx.doi.org/10.1007/s004360050276 | by applicant | US3219656 | US3839318 | AT382381B | AT386414B | WO9117271 | WO9119481 | WO9201047 | US5661130 | - "Posttranslational Modifications: Perspectives and Prospects", WOLD, F., POSTTRANSLATIONAL COVALENT MODIFICATION OF PROTEINS, ACADEMIC PRESS, (1983), page 1 12 | - SEIFTER ET AL., METH. ENZYMOL., (1990), vol. 182, page 626 646 | - RATTAN ET AL., "Protein Synthesis: Posttranslational Modifications and Aging", AM. N.Y. ACAD. SCI., (1992), vol. 663, page 48 62 | - HUSE ET AL., SCIENCE, (1989), vol. 246, page 1275 1281 | - WARD ET AL., NATURE, (1989), vol. 341, page 544 546 | - BRAIN RESEARCH, (1999), vol. 838, pages 27 - 36 | - ROSEVEAR ET AL., BIOCHEMISTRY, (1980), vol. 19, pages 4108 - 4115 | - KOELTZOW; URFER, J. AM. OIL CHEM. SOC., (1984), vol. 61, pages 1651 - 1655 | - LI ET AL., J. BIOL. CHEM., (1991), vol. 266, pages 10723 - 10726 | - GOPALAN ET AL., J. BIOL. CHEM., (1992), vol. 267, pages 9629 - 9638 | - CHEMICAL ABSTRACTS, Database accession no. 110:137536P | - GRUBER, H.; GREBER, G., "Reactive Sucrose Derivatives", CARBOHYDRATES AS ORGANIC RAW MATERIALS, pages 95 - 116 | - "Hydrogen Fluoride, Solvent and Reagent for Carbohydrate Conversion Technology", DEFAYE, J.; PEDERSON, C., Carbohydrates as Organic Raw Materials, VCH PUBLISHERS, (1991), pages 247 - 265 | - FERENCI, T., J. BACTERIOL, (1980), vol. 144, pages 7 - 11 | - TSUCHIYA, T., CHEM. PHARM. BULL., (1985), vol. 33, pages 503 - 508 | - BINDER, T. P.; ROBYT, J. F., CARBOHYDR. RES., (1985), vol. 140, pages 9 - 20 | - CHEMICAL ABSTRACTS, Database accession no. 108:114719 | - GRUBER; GREBER, NN, pages 95 - 116 | - GRUBER; GREBER, CHEM. ABSTR., pages 95 - 116 | - Remington's Pharmaceutical Sciences, MACK PUBLISHING CO | - TJERNBERG ET AL., J. BIOL. CHEM., (1999), vol. 274, pages 12619 - 12625 | - AINGE G; BOWLES, J.A.; MCCORMICK, S.G. ET AL., "Lack of deleterious effects of corticosteroid sprays containing benzalkonium chloride on nasal ciliated epithelium", DRUG INVEST, (1994), vol. 8, pages 127 - 33 | - ANDYA J; MAA, YF ET AL., "The effect of formulation excipients on protein stability and aerosol performance of spray-dried powders of a recombinant humanized anti-IgE monoclonal antibody", PHARM RES, (1999), vol. 16, no. 3, doi:doi:10.1023/A:1018805232453, pages 350 - 8, XP008003520 DOI: http://dx.doi.org/10.1023/A:1018805232453 | - ARAKAWA, T.; TIMASHEFF, S.N., "Stabilization of protein structure by sugars", BIOCHEMISTRY, (1982), vol. 21, page 6536 6544 | - ARAKAWA, T.; TIMASHEFF, S.N., "Stabilization of proteins by osmolytes", BIOPHYS. J., (1985), vol. 47, page 411414 | - BERG OH; HENRIKSEN, R.N.; STEINSVAG, S.K., "The effect of a benzalkonium chloride-containing nasal spray on human respiratory mucosa in vitro as a function of concentration and time of action", PHARMACOL TOXICOL, (1995), vol. 76, pages 245 - 9 | - BRAAT JP; AINGE, G.; BOWLES, J.A. ET AL., "The lack of effect of benzalkonium chloride on the cilia of the nasal mucosa in patients with perennial allergic rhinitis: A combined functional, light, scanning and transmission electron microscopy study", CLIN EXP ALLERGY, (1995), vol. 25, pages 957 - 65 | - BRENNEMAN, D.E.; J.M. BUZY; M.R. RUFF; C.B. PERT., "Peptide T sequences prevent neuronal cell death produced by the envelope protein (gp120) of the human immunodeficiency virus", DRUG DEVEL RES., (1988), vol. 15, doi:doi:10.1002/ddr.430150403, pages 361 - 369, XP055039001 DOI: http://dx.doi.org/10.1002/ddr.430150403 | - TP, HESELTINE PN; PARKER ES; EATON E; INGRAHAM LJ; GILL M; RUFF M; PERT CB; GOODWIN FK., "Improvement in AIDS patients on peptide T", LANCET, (1989), vol. 2, no. 8656, pages 226 - 7 | - CASADEVALL N ET AL., "Pure red-cell aplasia and antierythropoietin antibodies in patients treated with recombinant erythropoietin", N ENGL J MED, (2002), vol. 346, no. 7, doi:doi:10.1056/NEJMoa011931, pages 469 - 75, XP009073085 DOI: http://dx.doi.org/10.1056/NEJMoa011931 | - CHAWLA, A.S.; HINBERG, I.; BLAIS, P.; JOHNSON, D., "Aggregation of insulin, containing surfactants, in contact with different materials", DIABETES, (1985), vol. 34, doi:doi:10.2337/diabetes.34.5.420, pages 420 - 24, XP002919172 DOI: http://dx.doi.org/10.2337/diabetes.34.5.420 | - CLODFELTER, "Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide", PHARM RES, (1998), vol. 15, doi:doi:10.1023/A:1011918719017, pages 254 - 62, XP000945303 DOI: http://dx.doi.org/10.1023/A:1011918719017 | - CLODFELTER DK; PEKAR AH; REBHUN DM; DESTRAMPE KA; HAVEL HA; MYERS SR; BRADER ML., "Effects of non-covalent self-association on the subcutaneous absorption of a therapeutic peptide", PHARM RES, (1998), vol. 15, no. 2, doi:doi:10.1023/A:1011918719017, pages 254 - 62, XP000945303 DOI: http://dx.doi.org/10.1023/A:1011918719017 | - DEPALMA A, "Improving Stability While Adding Value", GENETIC ENG. NEWS, (20060115), vol. 26, no. 2 | - GRAF P; ENERDAL, J.; HALLEN, H., "Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis", ARCH OTOLARYNGOL HEAD NECK SURG, (1999), vol. 125, pages 1128 - 32 | - HESELTINE, P.N.; K. GOODKIN; J.H. ATKINSON; B. VITIELLO; J. ROCHON; R.K. HEATON; E.M. EATON; F.L. WILKIE; E. SOBEL; S.J. BROWN, "Randomized double-blind placebo-controlled trial of peptide T for HIV- associated cognitive impairment", ARCH NEUROL., (1998), vol. 55, pages 41 - 51 | - HOLM AF; FOKKENS, W.J.; GODTHELP, T. ET AL., "A 1-year placebo-controlled study of intranasal fluticasone propionate aqueous nasal spray in patients with perennial allergic rhinitis: A safety and biopsy study", CLIN OTOLATYNGOL, (1998), vol. 23, pages 69 - 73 | - KING HD; DUBOWCHIK GM; MASTALERZ H; WILLNER D; HOFSTEAD SJ; FIRESTONE RA; LASCH SJ; TRAIT PA, "Monoclonal antibody conjugates of doxorubicin prepared with branched peptide linkers: inhibition of aggregation by methoxytriethyleneglycol chains", J MED CHEM, (2002), vol. 45, no. 19, doi:doi:10.1021/jm020149g, pages 4336 - 43, XP001193748 DOI: http://dx.doi.org/10.1021/jm020149g | - KLOSSEK JM; LALIBERTE, F.; LALIBERTE, M.F. ET AL., "Local safety of intranasal triamcinolone acetonide: clinical and histological aspects of nasal mucosa in the long term treatment of perennial allergic rhinitis", RHINOLOGY, (2001), vol. 39, pages 17 - 22 | - KOSTEN TR; ROSEN MI; MCMAHON TL; BRIDGE TP; O'MALLEY SS; PEARSALL R; O'CONNOR PG., "Treatment of early AIDS dementia in intravenous drug users: high versus low dose peptide T", AM J DRUG ALCOHOL ABUSE, (1997), vol. 23, no. 4, pages 543 - 53 | - LANGE B; LUKAT, K.F.; BACHERT, C., "Local tolerability of a benzalkonium chloride-containing homeopathic nasal spray", ALLERGOLOGIE, (2004), vol. 27, no. 3, page 102 | - MARPLE B; ROLAND, P.; BENNINGER, M., "Safety review of benzalkonium chloride used as a preservative in i-ntranasal solutions: An overview of conflicting data and opinions", OTOLARYNGOLOGY- HEAD AND NECK SURGERY, (2004), vol. 130, no. 1, pages 131 - 141 | - MCMAHON C; DARBY, Y.; RYAN, R. ET AL., "Immediate and short-term effects of benzalkonium chloride on the human nasal mucosa in vivo", CLIN OTOLARYNGOL, (1997), vol. 22, pages 318 - 22 | - PERT CB; RUFF MR, "Peptide T[4-8]: a sequence in the AIDS virus envelope which blocks infectivity is essentially conserved across nine isolates", CLIN NEUROPHARMACOL, (1986), vol. 9, no. 4, pages 482 - 4 | - PERT CB; RUFF MR; HILL JM., "AIDS as a neuropeptide disorder: peptide T, VIP, and the HIV receptor", PSYCHOPHARMACOL BULL, (1988), vol. 24, no. 3, pages 315 - 9 | - PERT ET AL., "Chemokines receptor 5 antagonist D-ala Peptide T amide reduces microglia and astrocyte activation within the hippocampus in a neuroinflammatory rat model of Alzheimer's disease", NEUROSCIENCE, (2005), vol. 134, pages 671 - 676 | - PEZRON I; MITRA R; PAL D; MITRA AK, "Insulin aggregation and asymmetric transport across human bronchial epithelial cell monolayers (Calu-3", J PHARM SCI, (2002), vol. 91, no. 4, doi:doi:10.1002/jps.10114, pages 1135 - 46, XP002528202 DOI: http://dx.doi.org/10.1002/jps.10114 | - MARIA T. POLIANOVA; GIFFORD LEOUNG; SCOTT STRANG; CANDACE B. PERT; FRANCIS W. RUSCETTI; MICHAEL R. RUFF, "Anti-viral and immunological benefits in HIV patients receiving peptide", T PEPTIDES, (2003), vol. 24, no. 7, pages 1093 - 8 | - PORTER WR; STAACK H; BRANDT K; MANNING MC, "Thermal stability of low molecular weight uroldnase during heat treatment. I. Effects of protein concentration, pH and ionic strength", THROMB RES, (1993), vol. 71, no. 4, doi:doi:10.1016/0049-3848(93)90196-U, pages 265 - 79, XP026465030 DOI: http://dx.doi.org/10.1016/0049-3848(93)90196-U | - PUROHIT VS; MIDDAUGH CR; BALASUBRAMANIAN SV, "Influence of aggregation on immunogenicity of recombinant human Factor VIII in hemophilia A mice", J PHARM SCI, (2006), vol. 95, no. 2, pages 358 - 71 | - RIECHELMANN H; DEUTSCHLE, T.; STUHLMILLER, A.; GRONAU, S.; BURNER, H., "Nasal toxicity of benzalkonium chloride", AMERICAN JOURNAL OF RHINOLOGY, (2004), vol. 18, no. 5, pages 291 - 299 | - ROCCATANO ET AL., "Mechanism by which 2,2,2-trifluoroethanol/water mixtures stabilize secondary-structure ion-nation in peptides: A molecular dynamics study", PNAS, (2002), vol. 99, no. 19, pages 12179 - 12184 | - RAYCHAUDHURIA ET AL., "Immunomodulatory effects of Peptide T on Th 1/Th 2", CYTOKINES INTERNATIONAL JOURNAL OF IMMUNOPHARMACOLOGY, (1999), vol. 21, pages 609 - 615 | - REDWINE, LS; RONE, JD; PERT, CB; NIXON, R.; VANCE, M.; SANDLER, B.; LUMPKIN, MD; RUFF, MR., "GP120(V2)-Derived Peptide T Blocks GP120/CCR5 Chemokine Receptor Mediated Chemotaxis", CLINICAL IMMUNOLOGY., (1999), vol. 93, page 124 | - ROY S; JUNG R; KERWIN BA; RANDOLPH TW; CARPENTER JF, "Effects of benzyl alcohol on aggregation of recombinant human interleukin-1-receptor antagonist in reconstituted lyophilized formulations", J PHARM SCI, (2005), vol. 94, no. 2, pages 382 - 96 | - RUFF MR; HALLBERG PL; HILL JM; PERT CB, "Peptide T[4-8] is core HIV envelope sequence required for CD4 receptor attaclmient", LANCET, (1987), vol. 2, no. 8561, page 751 | - RUFF MR; MELENDEZ-GUERRERO LM; YANG QE; HO WZ; MIKOVITS JW; PERT CB; RUSCETTI FA, "Peptide T inhibits HIV-1 infection mediated by the chemokine receptor-5 (CCR5", ANTIVIRAL RES, (2001), vol. 52, no. 1, pages 63 - 75 | - RUFF MR; POLIANOVA M; YANG QB; LEOUNG GS; RUSCETTI FW; PERT CB, "Update On D-ala-peptide T-amide (DAPTA): a viral entry inhibitor that blocks CCR5 chemokine receptors", CURR HIV RES, (2003), vol. 1, no. 1, doi:doi:10.2174/1570162033352066, pages 51 - 67, XP002568509 DOI: http://dx.doi.org/10.2174/1570162033352066 | - RUFF MI; SMITH C; KINGAN T; JAFFE H; HESELTINE P; GILL MA; MAYER K; PERT CB; BRIDGE TP, "Pharmacokinetics of peptide T in patients with acquired immunodeficiency syndrome (AIDS", PROG NEUROPSYCHOPHARMACOL BIOL PSYCHIATRY, (1991), vol. 15, no. 6, doi:doi:10.1016/0278-5846(91)90008-O, pages 791 - 801, XP025531827 DOI: http://dx.doi.org/10.1016/0278-5846(91)90008-O | - SATO, S.; EBERT, C.D.; KIM, S.W., "Prevention of insulin self-association and surface adsorption", J. PHARM. SCI., (1983), vol. 72, pages 228 - 232 | - SIMPSON, D.M.; D. DORFMAN; R.K. OLNEY; G. MCKINLEY; J. DOBKIN; Y. SO; J. BERGER; M.B. FERDON; B. FRIEDMAN, "Peptide T in the treatment of painful distal neuropathy associated with AIDS: results of a placebo-controlled trial. The Peptide T Neuropathy Study Group", NEUROLOGY, (1996), vol. 47, pages 1254 - 1259 | - SLUZKY V; TAMADA JA; KLIBANOV AM; LANGER R., "Kinetics of insulin aggregation in aqueous solutions upon agitation in the presence of hydrophobic surfaces", PROC NATL ACAD SCI U S A, (1991), vol. 88, no. 21, doi:doi:10.1073/pnas.88.21.9377, pages 9377 - 81, XP055262764 DOI: http://dx.doi.org/10.1073/pnas.88.21.9377 | - SONNICHSEN FD; VAN EYK JE; HODGES RS; SYKES BD, "Effect of trifluoroethanol on protein secondary structure: an NMR and CD using a synthetic actin peptide", BIOCHEMISTRY, (1992), vol. 31, no. 37, pages 8790 - 8798 | - THUROW, H.; GEISEN, K., "Stabilization of dissolved proteins against denaturation at hydrophobic surfaces", DIABETOL, (1984), vol. 27, pages 212 - 218, XP001096189 | - WRIGHT J ET AL., "Identification of factors that contribute to recombinant AAV2 particle aggregation and methods to prevent its occurrence during vector purification and formulation", MOL THER, (2005), vol. 12, no. 1, doi:doi:10.1016/j.ymthe.2005.02.021, pages 171 - 8, XP004974961 DOI: http://dx.doi.org/10.1016/j.ymthe.2005.02.021 | - ZHANG MZ; WEN J; ARAKAWA T; PRESTRELSKI SJ., "A new strategy for enhancing the stability of lyophilized protein: the effect of the reconstitution medium on keratinocyte growth factor", PHARM RES, (1995), vol. 12, no. 10, doi:doi:10.1023/A:1016219000963, pages 1447 - 52, XP009007833 DOI: http://dx.doi.org/10.1023/A:1016219000963 |